Lack of Microbiological Controls Had Grave Consequences for Compounders
This article was originally published in The Gold Sheet
Executive Summary
The current public health crisis stemming from microbiological contamination of sterile injectables at drug compounding pharmacies demonstrate the importance of having robust aseptic sterile processing programs, said an FDA official. Some problems at drug manufacturers were also highlighted showing inadequate microbiological controls.